On February 21, the FDA announced that the shortage of semaglutide injection products has been resolved. Semaglutide has appeared on the FDA’s ...
The end of the official shortage status for semaglutide came as telehealth company Hims & Hers – which has been pushing sales ...
Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
Compounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...